PANews reported on October 11th that Aethir's co-founder announced that its digital asset reserve (DAT), Predictive Oncology (NASDAQ: POAI), has officially launched on the Nasdaq under the ticker symbol $POAI. Over the next 45 days, the reserve will purchase $45 million worth of $ATH from the open market. Earlier news reported that Predictive Oncology completed US$343.5 million in PIPE financing and plans to support the ATH token treasury strategy.PANews reported on October 11th that Aethir's co-founder announced that its digital asset reserve (DAT), Predictive Oncology (NASDAQ: POAI), has officially launched on the Nasdaq under the ticker symbol $POAI. Over the next 45 days, the reserve will purchase $45 million worth of $ATH from the open market. Earlier news reported that Predictive Oncology completed US$343.5 million in PIPE financing and plans to support the ATH token treasury strategy.

Aethir's digital asset library POAI is listed on Nasdaq, with plans to purchase $45 million in ATH

2025/10/11 10:29

PANews reported on October 11th that Aethir's co-founder announced that its digital asset reserve (DAT), Predictive Oncology (NASDAQ: POAI), has officially launched on the Nasdaq under the ticker symbol $POAI. Over the next 45 days, the reserve will purchase $45 million worth of $ATH from the open market.

Earlier news reported that Predictive Oncology completed US$343.5 million in PIPE financing and plans to support the ATH token treasury strategy.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like